Provost A
Dev Biol Stand. 1978;41:333-9.
For a whole series of reasons, most of which are political, the developing countries are following a policy of national self-sufficiency in veterinary vaccines. They are faced with problems at various levels: (1) at the level of logistic distribution, the developing countries suffer from a shortage of trained personnel, frequently lacking in enthusiasm, an often chronic shortage of funds; poorly equipped premises; poor maintenance of sophisticated but indispensable equipment (e.g. freeze-driers); a lack of facilities for cold storage and of distribution channels; field personnel with limited experience; (2) at the level of production, they must contend with difficulties in obtaining supplies of flasks and glassware; irregular supplies of water and electricity; difficulties in obtaining susceptible animals for quality control. The developing countries have found basically pragmatic solutions to these problems, such as the strict separation of the sites, materials and personnel involved in routine diagnosis and those involved in production; temporary foreign technical assistance, with or without financial aid; the use of simple, unsophisticated techniques, which are known to be reliable, even if somewhat outdated; manufacturing in bulk in multiple-dose bottles; research into the thermostabilisation of vaccine strains and the development of thermoprotective diluents for freeze-drying and reconstitution; the extensive use of combined vaccines; the establishment of production and control standards under the auspices of the WHO/FAO/OIE. In spite of these obstacles, the cost price is particularly low (from 0.20 to 0.35 francs per dose), which compares favourably with that of foreign private industry.
出于一系列原因,其中大部分是政治原因,发展中国家正在推行兽医疫苗国家自给自足政策。它们在各个层面都面临问题:(1) 在物流配送层面,发展中国家存在以下问题:缺乏训练有素的人员,这些人员往往缺乏热情,资金经常长期短缺;场所设备简陋;精密但不可或缺的设备(如冻干机)维护不善;缺乏冷藏设施和配送渠道;现场人员经验有限;(2) 在生产层面,它们必须应对以下困难:难以获得烧瓶和玻璃器皿供应;水电供应不稳定;难以获得用于质量控制的易感动物。发展中国家已找到基本务实的解决这些问题的办法,例如将常规诊断涉及的场所、材料和人员与生产涉及的场所、材料和人员严格分开;临时外国技术援助,无论有无财政援助;使用简单、不复杂但已知可靠的技术,即使这些技术有些过时;采用多剂量瓶批量生产;研究疫苗毒株的热稳定性以及开发用于冻干和复溶的热保护稀释剂;广泛使用联合疫苗;在世卫组织/粮农组织/国际兽疫局的支持下制定生产和控制标准。尽管存在这些障碍,但其成本价格特别低(每剂0.20至0.35法郎),与外国私营企业相比具有优势。